GlassScriptPhysician profile
Mary J Morey
NPI 1972500874
$10,430.93
in general payments reported to CMS, 2019-2025
41 companies · $2,412 in 2025
The $2,412 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,532 · 2022: $2,114 · 2023: $1,873 · 2024: $2,499 · 2025: $2,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,784.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,745.75 | 2021-2025 | |
| Janssen Biotech, INC. | $1,169.98 | 2021-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $995.24 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $849.55 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $577.52 | 2022-2025 | |
| Ardelyx, INC. | $377.66 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $310.48 | 2024-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $240.65 | 2021-2023 | |
| Madrigal Pharmaceuticals | $235.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $224.03 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $220.02 | 2022-2025 | |
| Braintree Laboratories, INC. | $192.67 | 2021-2024 | Sutab, Suflave |
| Amgen INC. | $188.56 | 2021-2023 | Amjevita, Avsola |
| Ironwood Pharmaceuticals, INC | $169.00 | 2021-2024 | Linzess |
| Janssen Scientific Affairs, LLC | $167.40 | 2022-2023 | Stelara |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $164.84 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $160.12 | 2024-2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.94 | 2021-2022 | |
| Insulet Corporation | $142.86 | 2025 | Omnipod |
| Organon LLC | $136.35 | 2022-2025 | Hadlima, Renflexis |
| Vivus LLC | $122.52 | 2021-2025 | Pancreaze |
| Qol Medical, LLC | $90.62 | 2023-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $89.42 | 2021-2024 | Recarbrio, Dificid, Zerbaxa |
| Inspire Medical Systems, INC. | $76.28 | 2025 | Inspire |
| Ipsen Biopharmaceuticals, INC | $70.48 | 2024-2025 | Iqirvo, Bylvay |
| Redhill Biopharma INC. | $68.93 | 2021-2023 | Movantik, Aemcolo, Talicia |
| Intercept Pharmaceuticals, INC. | $68.87 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $54.97 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $54.30 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $49.70 | 2024 | Idacio |
| Celgene Corporation | $47.43 | 2023-2024 | Zeposia |
| Boston Scientific Corporation | $32.48 | 2024 | Watchman Flx |
| Amag Pharmaceuticals, INC. | $27.62 | 2021 | |
| Sirtex Medical INC | $26.60 | 2025 | Sir-Spheres Microspheres |
| Novo Nordisk INC | $25.12 | 2025 | Wegovy |
| Pharmacosmos Therapeutics INC. | $21.59 | 2021 | |
| Alnylam Pharmaceuticals INC. | $19.55 | 2025 | Givlaari |
| Novartis Pharmaceuticals Corporation | $19.20 | 2023 | Leqvio |
| Sandoz INC. | $16.53 | 2023 | Hyrimoz |
| Echosens North America, INC. | $15.71 | 2025 | Fibroscan |
| Alfasigma USA, INC. | $15.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Morey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.